QQQ   354.74 (+0.78%)
AAPL   180.40 (+0.17%)
MSFT   334.43 (+0.56%)
META   274.04 (+0.52%)
GOOGL   124.88 (+0.94%)
AMZN   124.75 (+1.61%)
TSLA   215.95 (+4.06%)
NVDA   393.47 (-1.06%)
NIO   7.70 (+2.12%)
BABA   84.98 (+2.39%)
AMD   118.38 (-0.91%)
T   15.10 (-4.49%)
F   12.44 (+2.73%)
MU   68.93 (-0.23%)
CGC   0.84 (+0.74%)
GE   106.53 (+1.78%)
DIS   91.07 (+2.80%)
AMC   4.55 (+0.00%)
PFE   38.50 (+1.26%)
PYPL   64.07 (+1.62%)
NFLX   404.34 (+0.30%)
QQQ   354.74 (+0.78%)
AAPL   180.40 (+0.17%)
MSFT   334.43 (+0.56%)
META   274.04 (+0.52%)
GOOGL   124.88 (+0.94%)
AMZN   124.75 (+1.61%)
TSLA   215.95 (+4.06%)
NVDA   393.47 (-1.06%)
NIO   7.70 (+2.12%)
BABA   84.98 (+2.39%)
AMD   118.38 (-0.91%)
T   15.10 (-4.49%)
F   12.44 (+2.73%)
MU   68.93 (-0.23%)
CGC   0.84 (+0.74%)
GE   106.53 (+1.78%)
DIS   91.07 (+2.80%)
AMC   4.55 (+0.00%)
PFE   38.50 (+1.26%)
PYPL   64.07 (+1.62%)
NFLX   404.34 (+0.30%)
QQQ   354.74 (+0.78%)
AAPL   180.40 (+0.17%)
MSFT   334.43 (+0.56%)
META   274.04 (+0.52%)
GOOGL   124.88 (+0.94%)
AMZN   124.75 (+1.61%)
TSLA   215.95 (+4.06%)
NVDA   393.47 (-1.06%)
NIO   7.70 (+2.12%)
BABA   84.98 (+2.39%)
AMD   118.38 (-0.91%)
T   15.10 (-4.49%)
F   12.44 (+2.73%)
MU   68.93 (-0.23%)
CGC   0.84 (+0.74%)
GE   106.53 (+1.78%)
DIS   91.07 (+2.80%)
AMC   4.55 (+0.00%)
PFE   38.50 (+1.26%)
PYPL   64.07 (+1.62%)
NFLX   404.34 (+0.30%)
QQQ   354.74 (+0.78%)
AAPL   180.40 (+0.17%)
MSFT   334.43 (+0.56%)
META   274.04 (+0.52%)
GOOGL   124.88 (+0.94%)
AMZN   124.75 (+1.61%)
TSLA   215.95 (+4.06%)
NVDA   393.47 (-1.06%)
NIO   7.70 (+2.12%)
BABA   84.98 (+2.39%)
AMD   118.38 (-0.91%)
T   15.10 (-4.49%)
F   12.44 (+2.73%)
MU   68.93 (-0.23%)
CGC   0.84 (+0.74%)
GE   106.53 (+1.78%)
DIS   91.07 (+2.80%)
AMC   4.55 (+0.00%)
PFE   38.50 (+1.26%)
PYPL   64.07 (+1.62%)
NFLX   404.34 (+0.30%)
NASDAQ:VTVT

vTv Therapeutics (VTVT) Stock Forecast, Price & News

$0.81
-0.03 (-3.50%)
(As of 01:41 PM ET)
Compare
Today's Range
$0.80
$0.85
50-Day Range
$0.72
$0.95
52-Week Range
$0.61
$1.40
Volume
32,734 shs
Average Volume
102,972 shs
Market Capitalization
$84.76 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$4.00

vTv Therapeutics MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
376.5% Upside
$4.00 Price Target
Short Interest
Bearish
4.23% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
N/A
Insider Trading
N/A
Proj. Earnings Growth
N/A

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.39 out of 5 stars

Medical Sector

1883rd out of 1,980 stocks

Pharmaceutical Preparations Industry

941st out of 978 stocks


VTVT stock logo

About vTv Therapeutics (NASDAQ:VTVT) Stock

vTv Therapeutics, Inc. is a clinical-stage biopharmaceutical company engaged in the discovery and development of orally administered small molecule drug candidates to fill significant unmet medical needs. Its products target the treatment of central nervous system disorders, diabetes and metabolic disorders, inflammation, and cancer. It offers Azeliragon, TTP399, TTP273, HPP593, HPP737, and the Nrf2/Bach1 program. The company was founded on April 2, 2015 and is headquartered in High Point, NC.

Receive VTVT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for vTv Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

VTVT Stock News Headlines

The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
vTv Therapeutics (NASDAQ:VTVT) Now Covered by StockNews.com
vTv Therapeutics Insider Ups Holding During Year
vTv Therapeutics Insider Ups Holding During Year \
The Graphite Shortage Story You're Not Being Told
Graphite demand for EV batteries is expected to increase 10X from 2020 to 2030. And today, with NO graphite-producing mines in N. America, China has a stranglehold on our graphite supply. That's why the U.S. government is spending billions of dollars to ensure an adequate domestic supply of this metal that's vital for energy independence and national security.
vTv Therapeutics Inc Class A
VTVT.PH - | Stock Price & Latest News | Reuters
See More Headlines

VTVT Price History

VTVT Company Calendar

Last Earnings
5/11/2023
Today
6/02/2023
Next Earnings (Estimated)
8/21/2023
Fiscal Year End
12/31/2023

Industry, Sector and Symbol

Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:VTVT
Employees
9
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$4.00
High Stock Price Forecast
$6.00
Low Stock Price Forecast
$2.00
Forecasted Upside/Downside
+376.2%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-19,160,000.00
Pretax Margin
-119,016.66%

Debt

Sales & Book Value

Annual Sales
$2.02 million
Book Value
($0.18) per share

Miscellaneous

Free Float
103,740,000
Market Cap
$87.84 million
Optionable
Not Optionable
Beta
-1.20

Key Executives

  • Paul Jai Sekhri
    President, Chief Executive Officer & Director
  • Steven Tuch
    Chief Financial Officer
  • Carmen Valcarce
    Chief Scientific Officer & Executive VP
  • Elizabeth M. Keiley
    Executive Vice President & General Counsel
  • Vanessa McDade
    Chief Administration Officer













VTVT Stock - Frequently Asked Questions

Should I buy or sell vTv Therapeutics stock right now?

2 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for vTv Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" VTVT shares.
View VTVT analyst ratings
or view top-rated stocks.

What is vTv Therapeutics' stock price forecast for 2023?

2 brokerages have issued twelve-month price objectives for vTv Therapeutics' stock. Their VTVT share price forecasts range from $2.00 to $6.00. On average, they anticipate the company's stock price to reach $4.00 in the next twelve months. This suggests a possible upside of 376.2% from the stock's current price.
View analysts price targets for VTVT
or view top-rated stocks among Wall Street analysts.

How have VTVT shares performed in 2023?

vTv Therapeutics' stock was trading at $0.6628 at the beginning of the year. Since then, VTVT shares have increased by 26.7% and is now trading at $0.8399.
View the best growth stocks for 2023 here
.

When is vTv Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Monday, August 21st 2023.
View our VTVT earnings forecast
.

How were vTv Therapeutics' earnings last quarter?

vTv Therapeutics Inc. (NASDAQ:VTVT) released its earnings results on Thursday, May, 11th. The biotechnology company reported ($0.06) EPS for the quarter, beating analysts' consensus estimates of ($0.08) by $0.02.

What other stocks do shareholders of vTv Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other vTv Therapeutics investors own include VBI Vaccines (VBIV), OPKO Health (OPK), Sorrento Therapeutics (SRNE), Inovio Pharmaceuticals (INO), SCYNEXIS (SCYX), Onconova Therapeutics (ONTX), Vaxart (VXRT), Agile Therapeutics (AGRX) and Idera Pharmaceuticals (IDRA).

When did vTv Therapeutics IPO?

(VTVT) raised $125 million in an initial public offering on Thursday, July 30th 2015. The company issued 7,800,000 shares at $15.00-$17.00 per share. Piper Jaffray and Stifel acted as the underwriters for the IPO and Canaccord Genuity and Janney Montgomery Scott were co-managers.

What is vTv Therapeutics' stock symbol?

vTv Therapeutics trades on the NASDAQ under the ticker symbol "VTVT."

How do I buy shares of vTv Therapeutics?

Shares of VTVT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is vTv Therapeutics' stock price today?

One share of VTVT stock can currently be purchased for approximately $0.84.

How much money does vTv Therapeutics make?

vTv Therapeutics (NASDAQ:VTVT) has a market capitalization of $87.84 million and generates $2.02 million in revenue each year. The biotechnology company earns $-19,160,000.00 in net income (profit) each year or ($0.21) on an earnings per share basis.

How can I contact vTv Therapeutics?

vTv Therapeutics' mailing address is 3980 PREMIER DR SUITE 310, HIGH POINT NC, 27265. The official website for the company is www.vtvtherapeutics.com. The biotechnology company can be reached via phone at (336) 841-0300, via email at ir@vtvtherapeutics.com, or via fax at 336-841-0310.

This page (NASDAQ:VTVT) was last updated on 6/2/2023 by MarketBeat.com Staff

My Account -